This is a working overview of anxiolytic, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-19. Anything still debated is marked as such rather than presented as settled.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Modeled on tuftsin |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues |
| Approximate molecular mass | Around 750 Da | Depends on counter-ion and hydration |
| Common forms | Lyophilized powder | Also described as aqueous solution |
| Primary origin of research | Russian laboratories | Mid-1990s onward |
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
=== Background === Walter (Walt) A. Anderson (1880–1963), a cook, had been running food stands in Wichita since 1916, when he opened his first diner in a converted streetcar. After a second and third location, he was looking to open a fourth location when he met Edgar Waldo "Billy" A. Ingram (1880–1966), an insurance and real-estate man, and together they started the White Castle chain.
==== Lecanemab ==== Lecanemab (BAN2401), is a humanized mAb that selectively targets toxic soluble Aβ protofibrils, In phase 3 clinical trials, Lecanemab showed a 27% slower cognitive decline after 18 months of treatment in comparison to placebo. The phase 3 clinical trials also reported infusion related reactions, amyloid-related imaging abnormalities and headaches as the most common side effects of Lecanemab. In July 2023 the FDA gave Lecanemab full approval for the treatment of Alzheimer's Disease and it was given the commercial name Leqembi.
=== Anastrozole === Anastrozole, brand name Arimidex, is a type of anti-estrogen used in treatment of breast cancer but is also used by bodybuilders to combat the estrogenic side effects associated with using anabolic steroids.
Rapid evolutionary divergence, along with the multiple and parallel loss of orthologs in some lineages, can give the false appearance of the emergence of a novel gene from scratch. Recent syntheses highlight both rapid progress and ongoing debates in de novo gene research, including challenges in identification, functional validation, and links to microproteins and random-peptide experiments.
The study Does Overfilling Smooth Inflatable Saline-filled Breast Implants Decrease the Deflation Rate? Experience with 4,761 Augmentation Mammaplasty Patients reported that overfilling the prosthetic breast with saline solution (by approx. 10–13%) reduced the rate of rupture-and-deflation to one-point-eighty-three per cent (1.83%) at the eight-year mark after the surgery.
Sources: en.wikipedia.org
== Clinical Significance == Diseases affecting the carnitine shuttle include carnitine palmitoyltransferase I deficiency, carnitine palmitoyltransferase II deficiency, and carnitine-acylcarnitine translocase deficiency, among others. A common symptom among them includes fatigue that presents as an intolerance to physical exertion, with symptoms varying wildly between the main three. Treatment usually consists of dietary supplements, avoidance of fasting and prolonged exercise, and treatment of complications, such as myoglobinuria, hypoglycemia, and hepatic dysfunction. CPT1A has also been investigated as a therapeutic target in cancer. In prostate cancer models, inhibition of CPT1A by the cisplatin prodrug Platin-L suppressed fatty-acid oxidation and increased cellular dependence on glucose.
Positron emission tomography (PET) is a functional imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption. In clinical practice it is used to diagnose and manage cancer treatment, in cardiology and cardiac surgery, and in neurology and psychiatry. PET is a common imaging technique, a medical scintillography technique used in nuclear medicine. A radiopharmaceutical—a radioisotope attached to a drug—is injected into the body as a tracer. When the radiopharmaceutical undergoes beta plus decay, a positron is emitted, and when the positron interacts with an ordinary electron, the two particles annihilate and two gamma rays are emitted in opposite directions. These gamma rays are detected by two gamma cameras to form a three-dimensional image. PET scanners can incorporate a computed tomography scanner (CT) and are known as PET–CT scanners. PET scan images can be reconstructed using a CT scan performed using one scanner during the same session. One of the disadvantages of a PET scanner is its high initial cost and ongoing operating costs.
This mutation causes fewer GAG chains to be added to HSPGs and CSPGs, meaning there are fewer complexes available to closely regulate the maturation of chondrocytes. Incorrect signals are sent to chondrocytes in the cartilage anlage because the GAG chain and proteoglycan complexes are unable to work properly and cause the chondrocytes to mature and ossify too quickly. The correct amount of chondrocytes are not able to gather in the cartilage anlage, leading to a shortage of cartilage for ossification and eventually shorter bones. While the pug mutation deals with the pre-maturation of chondrocytes, multiple other mutations alter chondrocyte proliferation. One such example, the point mutation G380R located on the fibroblast growth factor receptor 3 (FGFR-3) gene leads to achondroplasia, a type of dwarfism. Achondroplasia is either caused through a spontaneous mutation or inherited in an autosomal dominant fashion. Both the homozygous dominant and the heterozygous genotypes exhibit achondroplasia symptoms, but the heterozygotes are often milder. Individuals with the mutated allele(s) display a variety of symptoms of the failure of endochondral ossification, including the shortening of proximal long limbs and midface hypoplasia. The non-mutated FGFR-3 gene is responsible for the expression of fibroblast growth factors (FGFs) which has to maintain a certain level to ensure that the proliferation of chondrocytes happens accordingly. The G380R mutation causes FGFR-3 to over express FGFs and the balance within the cartilage extracellular matrix is thrown off.
=== Diagnostics === As anti-angiogenic cancer therapies have achieved widespread use, there has been increased interest in non-invasive monitoring of angiogenesis. One of the most extensively examined targets of angiogenesis is integrin αVβ3. Radiolabeled peptides containing RGD show high affinity and selectivity for integrin αVβ3 and are being investigated as tools to monitor treatment response of tumors via PET imaging. These include 18F-Galacto-RGD, 18F-Fluciclatide-RGD, 18F-RGD-K5, 68Ga-NOTA-RGD, 68Ga-NOTA-PRGD2, 18F-Alfatide, 18F-Alfatide II, and 18F-FPPRGD2. In a meta-analysis of studies using PET/CT in patients with cancer, it was shown that this diagnostic method may be very useful for detecting malignancies and predicting short-term outcomes, although larger-scale studies are needed.
Kruja, headquartered at the tekke of Fushë-Krujë Elbasan, headquartered at the tekke of Krastë, Dibër Korça, headquartered at the tekke of Melçan Gjirokastra, headquartered at the tekke of Asim Baba Prishta, representing Berat and part of Përmet Vlora, headquartered at the tekke of Frashër National headquarters in other countries are located in:
Sources: en.wikipedia.org
March 11: Decree improving breastfeeding conditions in industrial and commercial establishments (dedicated rooms, breastfeeding facilities, cribs, and qualified staff). December 3: Decree enacting the International Convention for the Suppression of the Traffic in Women and Children (signed September 30, 1921); France adhered in January 1926 with reservations regarding colonies, protectorates, or mandates. December 7: Law amending Article 72 of Book II of the Labor and Social Welfare Code (list of jobs prohibited to children under 18 and to women). December 1: Maritime Labor Code; a married woman may not board a ship without her husband's permission—or court authorization. 1927
=== 4. Alveolar bone (alveolar process) === The alveolar bone forms part of the maxilla and mandible and provides the osseous support for the teeth by forming their sockets. Its structure and density are maintained by functional forces transmitted through the periodontal ligament. In periodontitis, inflammatory mediators released during the host immune response stimulate osteoclastic activity, leading to alveolar bone resorption. This irreversible loss of supporting bone is a hallmark of clinical attachment loss and represents the most significant structural consequence of periodontal disease.
== Clinical Significance == Diseases affecting the carnitine shuttle include carnitine palmitoyltransferase I deficiency, carnitine palmitoyltransferase II deficiency, and carnitine-acylcarnitine translocase deficiency, among others. A common symptom among them includes fatigue that presents as an intolerance to physical exertion, with symptoms varying wildly between the main three. Treatment usually consists of dietary supplements, avoidance of fasting and prolonged exercise, and treatment of complications, such as myoglobinuria, hypoglycemia, and hepatic dysfunction. CPT1A has also been investigated as a therapeutic target in cancer. In prostate cancer models, inhibition of CPT1A by the cisplatin prodrug Platin-L suppressed fatty-acid oxidation and increased cellular dependence on glucose.
The compound was first administered to two normal human volunteers by Abass Alavi in August 1976 at the University of Pennsylvania. Brain images obtained with an ordinary (non-PET) nuclear scanner demonstrated the concentration of FDG in that organ. Later, the substance was used in dedicated positron tomographic scanners, to yield the modern procedure. The logical extension of positron instrumentation was a design using two two-dimensional arrays. PC-I was the first instrument using this concept and was designed in 1968, completed in 1969 and reported in 1972. The first applications of PC-I in tomographic mode as distinguished from the computed tomographic mode were reported in 1970. It soon became clear to many of those involved in PET development that a circular or cylindrical array of detectors was the logical next step in PET instrumentation. Although many investigators took this approach, James Robertson and Zang-Hee Cho were the first to propose a ring system that has become the prototype of the current shape of PET. The first multislice cylindrical array PET scanner was completed in 1974 at the Mallinckrodt Institute of Radiology by the group led by Ter-Pogossian. The PET–CT scanner, attributed to David Townsend and Ronald Nutt, was named by Time as the medical invention of the year in 2000.
Sources: en.wikipedia.org
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.
It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.
No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.